Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Bastien Oriano"'
Autor:
David Russo, Stéphane Dalle, Olivier Dereure, Laurent Mortier, Sophie Dalac-Rat, Caroline Dutriaux, Marie-Thérèse Leccia, Delphine Legoupil, Henri Montaudié, Eve Maubec, Julie De Quatrebarbes, Jean-Philippe Arnault, Florence Granel Brocard, Philippe Saïag, Brigitte Dreno, Clara Allayous, Bastien Oriano, Wendy Lefevre, Céleste Lebbé, Lise Boussemart
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe tumor mutational burden (TMB) is high in melanomas owing to UV-induced oncogenesis. While a high TMB is a predictive biomarker of response to PD-1 inhibitors, it may be associated with the rise of resistant clones to targeted therapy ov
Externí odkaz:
https://doaj.org/article/f844a1fc7d06416ea3d2882e024c7f02
Autor:
Marie Robin, Raphael Porcher, David Michonneau, Laetitia Taurines, Flore Sicre de Fontbrune, Aliénor Xhaard, Bastien Oriano, Aurélien Sutra Del Galy, Régis Peffault de Latour, Gérard Socié, Marie-Hélène Schlageter
Publikováno v:
Blood advances. 6(16)
Acute graft-versus-host disease (GVHD) is still the major contributor to comorbidities and mortality after allogeneic hematopoietic stem cell transplantation. The use of plasmatic biomarkers to predict early outcomes has been advocated in the past de
Autor:
Léo Plaçais, Stéphane Dalle, Olivier Dereure, Sabiha Trabelsi, Sophie Dalac, Delphine Legoupil, Henri Montaudié, Jean-Philippe Arnault, Julie De Quatrebarbes, Philippe Saiag, Florence Brunet-Possenti, Thierry Lesimple, Eve Maubec, François Aubin, Florence Granel-Brocard, Jean-Jacques Grob, Pierre-Emmanuel Stoebner, Clara Allayous, Bastien Oriano, Caroline Dutriaux, Laurent Mortier, Céleste Lebbe
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 2022, 81 (10), pp.1445-1452. ⟨10.1136/ard-2022-222186⟩
Annals of the Rheumatic Diseases, 2022, 81 (10), pp.1445-1452. ⟨10.1136/ard-2022-222186⟩
ObjectiveTo quantify the risk of immune-related adverse events (irAEs) in patients with pre-existing autoimmune disease (pAID) treated by immune checkpoint inhibitors (ICIs) for stage III or IV melanoma.MethodsCase–control study performed on a Fren
Autor:
Julie De Quatrebarbes, Florence Granel Brocard, Sabiha Trabelsi, P.-E. Stoebner, Eve Maubec, Clara Allayous, Thierry Lesimple, Jean-Philippe Arnault, Sophie Dalac, Florence Brunet Possenti, Delphine Legoupil, Léo Plaçais, Henri Montaudié, Brigitte Dreno, F. Aubin, Céleste Lebbé, Olivier Dereure, Laurent Mortier, S. Dalle, Philippe Saiag, Jean-Jacques Grob, Bastien Oriano, Caroline Dutriaux
Publikováno v:
Annales de Dermatologie et de Vénéréologie - FMC. 1:A74-A75
Autor:
Caroline Dutriaux, Céleste Lebbé, Marie-Thérèse Leccia, Wendy Lefevre, David Russo, Olivier Dereure, Julie De Quatrebarbes, Delphine Legoupil, Philippe Saiag, Clara Allayous, S. Dalac-Rat, Laurent Mortier, S. Dalle, Eve Maubec, Florence Granel Brocard, Bastien Oriano, Jean-Philippe Arnault, Lise Boussemart, Henri Montaudié, Brigitte Dreno
Publikováno v:
Annales de Dermatologie et de Vénéréologie - FMC. 1:A130-A131
Introduction En raison de l’oncogenese induite par les rayons ultraviolets, la charge mutationnelle tumorale est classiquement elevee dans les melanomes cutanes. Elevee, elle est un biomarqueur predictif de reponse aux anti-PD-1, mais une telle ric
Autor:
Perrine Rousset, Stéphane Dalle, Laurent Mortier, Olivier Dereure, Sophie Dalac, Caroline Dutriaux, Marie Thérèse Leccia, Delphine Legoupil, Vincent Descamps, Julie De Quatrebarbes, Jean-Jacques Grob, Philippe Saiag, Eve Maubec, Pierre-Emmanuel Stoebner, Florence Granel Brocard, Jean-Philippe Arnault, Clara Allayous, Bastien Oriano, Celeste Lebbe, Henri Montaudie
Publikováno v:
Journal of Clinical Oncology. 40:9556-9556
9556 Background: Melanoma of unknown primary (MUP) account for 3% of all melanomas. Clinical outcome of advanced MUP in the era of novel therapies including immunotherapies (ICI) and targeted therapies (TT) have been only scarcely studied, whereas a
Autor:
Céleste Lebbé, Anais Vallet, Raphaël Porcher, D. Legoupil, Thierry Lesimple, Bernard Guillot, Philippe Saiag, Jean-Philippe Lacour, Eve Maubec, Caroline Dutriaux, Florence Brunet-Possenti, Marie-Thérèse Leccia, Brigitte Dréno, Julie De Quatrebarbes, Bastien Oriano, Florence Granel-Brocard, Jean-Philippe Arnault, for MelBase, Laurent Mortier, Pierre-Emmanuel Stoebner, Clara Allayous, Stéphane Dalle, Sophie Dalac, François Aubin
Publikováno v:
JAMA Dermatol
JAMA Dermatology
JAMA Dermatology, American Medical Association, 2019, 155 (6), pp.673. ⟨10.1001/jamadermatol.2019.0425⟩
JAMA Dermatology
JAMA Dermatology, American Medical Association, 2019, 155 (6), pp.673. ⟨10.1001/jamadermatol.2019.0425⟩
International audience; The prognosis of advanced melanoma has been greatly improved by new therapeutic agents and clinicians rely on dynamic signals to drive their therapeutic choices. Although the kinetics of metastatic disease seem to be correlate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d50085cf7a593e61cdb95478601f942
https://europepmc.org/articles/PMC6495357/
https://europepmc.org/articles/PMC6495357/
Autor:
Stéphane Dalle, Raphaël Porcher, Thierry Lesimple, Marie-Thérèse Leccia, Jean-Philippe Lacour, Sophie Dalac, D. Legoupil, Pauline Tétu, Sameh Mohamed, A. Ballon, Florence Brunet-Possenti, Céleste Lebbé, Clara Allayous, Laurent Mortier, François Aubin, Julie De Quatrebarbes, Pierre-Emmanuel Stoebner, Caroline Dutriaux, Bastien Oriano, Brigitte Dréno, Bernard Guillot, Philippe Saiag, Marie Beylot-Barry
Publikováno v:
European Journal of Cancer
European Journal of Cancer, Elsevier, 2019, 112, pp.38-46. ⟨10.1016/j.ejca.2019.02.009⟩
European Journal of Cancer, 2019, 112, pp.38-46. ⟨10.1016/j.ejca.2019.02.009⟩
European Journal of Cancer, Elsevier, 2019, 112, pp.38-46. ⟨10.1016/j.ejca.2019.02.009⟩
European Journal of Cancer, 2019, 112, pp.38-46. ⟨10.1016/j.ejca.2019.02.009⟩
International audience; Background: Melanoma brain metastases (MBMs) are historically associated with poor prognosis. Radiation therapy is conventionally associated with a high local control rate. Development of targeted therapy and immunotherapy has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4740f4de3a0995fc1c93c6462b8f58e5
https://hal.umontpellier.fr/hal-02872129/file/S0959804919301716.pdf
https://hal.umontpellier.fr/hal-02872129/file/S0959804919301716.pdf
Autor:
Céleste Lebbé, Joanna Mangana, Pauline Tétu, Stéphane Dalle, Reinhard Dummer, Nathalie Beneton, Nicolas Meyer, Bastien Oriano, Caroline Dutriaux, Olivier Michielin
Publikováno v:
European journal of cancer (Oxford, England : 1990). 93